ABG
MGNX icon

Ally Bridge Group’s MacroGenics MGNX Stock Holding History

Ally Bridge Group’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-30,000
Closed -$482K – 25
2021
Q4 		$482K Sell
30,000
-335,000
-92% -$6.31M 0.17% 30
2021
Q3 		$7.64M Buy
365,000
+252,161
+223% +$6.07M 2.25% 22
2021
Q2 		$3.03M Buy
+112,839
New +$3.3M 0.75% 29

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ally Bridge Group's MGNX Position: Q1 2022 in Review

Ally Bridge Group sold out of MacroGenics (MGNX) in Q1 2022, closing a stake of 30,000 shares — an estimated $482K sold.

Ally Bridge Group first reported a position in MGNX in Q2 2021 and held it in 3 quarters. The position peaked at $7.64M in Q3 2021. 144 funds tracked by Wall St. Rank hold MGNX as of Q1 2022.

  • Ally Bridge Group reported no remaining MacroGenics position as of Q1 2022 after selling out during the quarter.
  • Ally Bridge Group sold 30,000 MacroGenics shares in Q1 2022, an estimated $482K.
  • Ally Bridge Group first reported a position in MacroGenics in Q2 2021 and held it in 3 quarters.
  • Ally Bridge Group's MacroGenics position peaked at $7.64M in Q3 2021.
  • 144 funds tracked by Wall St. Rank held MacroGenics as of Q1 2022.

Based on Ally Bridge Group's 13F filing for Q1 2022, filed 16 May 2022.